AAAAAA
Results: 1-25/48
Authors:
Zhang, YJ
Zhang, LQ
Ketas, T
Korber, BTM
Moore, JP
Citation: Yj. Zhang et al., HIV type 1 molecular clones able to use the Bonzo/STRL-33 coreceptor for virus entry, AIDS RES H, 17(3), 2001, pp. 217-227
Authors:
LaBranche, CC
Galasso, G
Moore, JP
Bolognesi, DP
Hirsch, MS
Hammer, SM
Citation: Cc. Labranche et al., HIV fusion and its inhibition, ANTIVIR RES, 50(2), 2001, pp. 95-115
Authors:
Spenlehauer, C
Gordon, CA
Trkola, A
Moore, JP
Citation: C. Spenlehauer et al., A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1, VIROLOGY, 280(2), 2001, pp. 292-300
Authors:
Strizki, JM
Xu, S
Wagner, NE
Wojcik, L
Liu, J
Hou, Y
Endres, M
Palani, A
Shapiro, S
Clader, JW
Greenlee, WJ
Tagat, JR
McCombie, S
Cox, K
Fawzi, AB
Chou, CC
Pugliese-Sivo, C
Davies, L
Moreno, ME
Ho, DD
Trkola, A
Stoddart, CA
Moore, JP
Reyes, GR
Baroudy, BM
Citation: Jm. Strizki et al., SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo, P NAS US, 98(22), 2001, pp. 12718-12723
Authors:
Zwick, MB
Labrijn, AF
Wang, M
Spenlehauer, C
Saphire, EO
Binley, JM
Moore, JP
Stiegler, G
Katinger, H
Burton, DR
Parren, PWHI
Citation: Mb. Zwick et al., Broadly neutralizing antibodies targeted to the membrane-proximal externalregion of human immunodeficiency virus type 1 glycoprotein gp41, J VIROLOGY, 75(22), 2001, pp. 10892-10905
Authors:
Parker, CE
Deterding, LJ
Hager-Braun, C
Binley, JM
Schulke, N
Katinger, H
Moore, JP
Tomer, KB
Citation: Ce. Parker et al., Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5, J VIROLOGY, 75(22), 2001, pp. 10906-10911
Authors:
Trkola, A
Ketas, TJ
Nagashima, KA
Zhao, L
Cilliers, T
Morris, L
Moore, JP
Maddon, PJ
Olson, WC
Citation: A. Trkola et al., Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140, J VIROLOGY, 75(2), 2001, pp. 579-588
Authors:
Parren, PWHI
Marx, PA
Hessell, AJ
Luckay, A
Harouse, J
Cheng-Mayer, C
Moore, JP
Burton, DR
Citation: Pwhi. Parren et al., Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro, J VIROLOGY, 75(17), 2001, pp. 8340-8347
Authors:
Moore, JP
Parren, PWHI
Burton, DR
Citation: Jp. Moore et al., Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development, J VIROLOGY, 75(13), 2001, pp. 5721-5729
Authors:
Freeman, ML
DiSario, JA
Nelson, DB
Fennerty, MB
Lee, JG
Bjorkman, DJ
Overby, CS
Aas, J
Ryan, ME
Bochna, GS
Shaw, MJ
Snady, HW
Erickson, RV
Moore, JP
Roel, JP
Citation: Ml. Freeman et al., Risk factors for post-ERCP pancreatitis: a prospective, multicenter study, GASTROIN EN, 54(4), 2001, pp. 425-434
Authors:
Moore, JP
Stevenson, M
Citation: Jp. Moore et M. Stevenson, New targets for inhibitors of HIV-1 replication, NAT REV MOL, 1(1), 2000, pp. 40-49
Authors:
Moore, JP
Doms, RW
Citation: Jp. Moore et Rw. Doms, HIV: Much at stake with kidneys?, J AM S NEPH, 11(11), 2000, pp. 2138-2140
Authors:
Schiller, DS
Binley, JM
Roux, KH
Adamson, CS
Jones, IM
Krausslich, HG
Hurley, A
Markowitz, M
Moore, JP
Citation: Ds. Schiller et al., Parameters influencing measurement of the Gag antigen-specific T-proliferative response to HIV type 1 infection, AIDS RES H, 16(3), 2000, pp. 259-271
Authors:
Martinson, JJ
Hong, L
Karanicolas, R
Moore, JP
Kostrikis, LG
Citation: Jj. Martinson et al., Global distribution of the CCR2-64I/CCR5-59653T HIV-1 disease-protective haplotype, AIDS, 14(5), 2000, pp. 483-489
Authors:
O'Brien, SJ
Moore, JP
Citation: Sj. O'Brien et Jp. Moore, The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS, IMMUNOL REV, 177, 2000, pp. 99-111
Authors:
Binley, JM
Clas, B
Gettie, A
Vesanen, M
Montefiori, DC
Sawyer, L
Booth, J
Lewis, M
Marx, PA
Bonhoeffer, S
Moore, JP
Citation: Jm. Binley et al., Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia, VIROLOGY, 270(1), 2000, pp. 237-249
Authors:
Delaney, M
Grinberg, L
Harrington, M
Morris, L
Wainberg, MA
Moore, JP
Citation: M. Delaney et al., Why are AIDS dissidents still making 15-year-old, long-refuted claims?, NATURE, 408(6810), 2000, pp. 287-287
Authors:
Dragic, T
Trkola, A
Thompson, DAD
Cormier, EG
Kajumo, FA
Maxwell, E
Lin, SW
Ying, WW
Smith, SO
Sakmar, TP
Moore, JP
Citation: T. Dragic et al., A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5, P NAS US, 97(10), 2000, pp. 5639-5644
Authors:
Ye, YJ
Si, ZH
Moore, JP
Sodroski, J
Citation: Yj. Ye et al., Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo, J VIROLOGY, 74(24), 2000, pp. 11955-11962
Authors:
Binley, JM
Sanders, RW
Clas, B
Schuelke, N
Master, A
Guo, Y
Kajumo, F
Anselma, DJ
Maddon, PJ
Olson, WC
Moore, JP
Citation: Jm. Binley et al., A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure, J VIROLOGY, 74(2), 2000, pp. 627-643
Authors:
Zhang, YJ
Lou, B
Lal, RB
Gettie, A
Marx, PA
Moore, JP
Citation: Yj. Zhang et al., Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primarycells, J VIROLOGY, 74(15), 2000, pp. 6893-6910
Authors:
Sanders, RW
Schiffner, L
Master, A
Kajumo, F
Guo, Y
Dragic, T
Moore, JP
Binley, JM
Citation: Rw. Sanders et al., Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bondbetween the gp120 and gp41 subunits, J VIROLOGY, 74(11), 2000, pp. 5091-5100
Authors:
Binley, JM
Trkola, A
Ketas, T
Schiller, D
Clas, B
Little, S
Richman, D
Hurley, A
Markowitz, M
Moore, JP
Citation: Jm. Binley et al., The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection, J INFEC DIS, 182(3), 2000, pp. 945-949
Authors:
Binley, JM
Schiller, DS
Ortiz, GM
Hurley, A
Nixon, DF
Markowitz, MM
Moore, JP
Citation: Jm. Binley et al., The relationship between T cell proliferative responses and plasma viremiaduring treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy, J INFEC DIS, 181(4), 2000, pp. 1249-1263
Authors:
Doms, RW
Moore, JP
Citation: Rw. Doms et Jp. Moore, HIV-1 membrane fusion: Targets of opportunity, J CELL BIOL, 151(2), 2000, pp. F9-F13